CAMBRIDGE, MA – September 18, 2019 – More than 30 life sciences executives gathered in Cambridge last week to discuss clinical, regulatory, operational and market uncertainties – key reasons why traditional S&OP processes often fall short for this industry. The conversation was led by Hugh Wight, Vice President of CMC at Allena Pharmaceuticals Chris Silva, Vice President of Procurement & Supply Chain at Akebia Therapeutics, and Todd Applebaum, Managing Director at Converge Consulting.
The conversation identified best practices for emerging companies navigating the planning environment, such as:
- Improving end-to-end visibility to address the structural network and regulatory constraints.
- Moving beyond balancing supply and demand to speed decision making and increase agility.
- Substituting planning excellence for inventory for high-value therapies and to tackle the squeeze on margins.
“A fit for purpose planning process helps emerging and growing life sciences companies navigate clinical trials, commercialization and global expansion more effectively,” said Applebaum. “Demand & Supply Planning is such a critical business process that companies often rely on traditional approaches due to the sense of urgency and necessity without consideration of alternatives. It is a high-risk situation where working with an experienced partner can make a world of difference.”
The event was hosted by Converge Consulting at the Boston Marriott Cambridge 5pm on September 12, 2019. Converge will be hosting such workshops periodically, into 2020 and beyond.
For more information on implementing planning best practice or future Converge events, contact Sarah Dedrick at email@example.com.
Converge Consulting serves the Life Sciences industry with strategy, operations and execution expertise. We collaborate with biotech, pharmaceutical and cell/gene therapy companies to achieve your important business objectives. The Converge approach focuses on bridging the gap between sound strategy and reliable execution. www.convergeconsulting.com
Rachel S. Borman